PT  - JOURNAL ARTICLE
AU  - Rebeca Carter
AU  - Angelina Mouralidarane
AU  - Shuvra Ray
AU  - Junpei Soeda
AU  - Jude Oben
TI  - Recent advancements in drug treatment of obesity
AID  - 10.7861/clinmedicine.12-5-456
DP  - 2012 Oct 01
TA  - Clinical Medicine
PG  - 456--460
VI  - 12
IP  - 5
4099  - http://www.rcpjournals.org/content/12/5/456.short
4100  - http://www.rcpjournals.org/content/12/5/456.full
SO  - Clin Med2012 Oct 01; 12
AB  - The prevalence of obesity is rising worldwide, with the UK having the highest prevalence in Europe. Obesity is associated with significant morbidity and has substantial healthcare implications, with current projections estimating that by 2030 obesity will cost the NHS approximately £2 billion each year. Lifestyle modification remains the cornerstone of anti-obesity treatment, but drugs can be introduced as adjuncts to assist and maintain weight loss. Some 1.45 million obesity-related prescriptions were dispensed in 2009, highlighting the high demand for obesity pharmacotherapy. At present, the lipase inhibitor orlistat (Xenical) is the only UK-approved long-term medical therapy for obesity. Double-blind clinical trials have shown that orlistat significantly increases weight loss compared to placebo, but the array of adverse side effects associated with orlistat limits its tolerability. The need for more effective and better-tolerated anti-obesity medications is clear and six therapies have reached phase-III trials.